4D Path Secures First Action Allowance Patent to Process Digital Whole Slide Images


January 14, 2020 — 4D Path today announced that the United States Patent and Trademark Office (USPTO) has approved the company’s utility patent (Patent No. US 10,535,434 B2) application on a First Action Allowance. 4D Path’s new scientific approach applies the patented technology to process digital whole slide images (WSIs) of H&E stained, formalin-fixed, paraffin embedded (FFPE) biopsy/resection specimens – a method of slide preparation and digital capture that remains unchanged from best practices that are used in pathology laboratories worldwide in today’s standard of care. Under the Patent Cooperation Treaty (PCT), following the USPTO’s approval 4D Path has also filed for IP in Canada and Europe (both pending).

4D Path’s patented method and integrated platform combine universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints that can inform treatment selection as well as stratify patients for novel targeted therapies without the need for a training dataset or human intervention. This cloud-based, quantitative approach provides clinical solutions in both companion diagnostics and translational medicine without adding extra load to reduce the cost, time and complexity of patient management, clinical trials and pharmaceutical efficacy discovery.

“We are excited to secure the allowance and issuance of a patent, obtained on an impressive First Action Allowance, by the United State Patent Office,” said Rodrigo Navarro, CEO of 4D Path. “Our novel technology represents a major scientific breakthrough – enabling the ability to characterize underlying fundamental processes across cancer spectra in many organ systems for the identification of any cancer type, its prognostic significant subtypes, variants, grades, molecular profile with overexpression status as well as benign lesions, all from the WSI. This not only significantly increases accuracy in cancer diagnosis, but also marks a new path forward in precision medicine and personalized treatment, at the time of the biopsy!”